Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR Exon 20 S768I Mutant Lung Adenocarcinoma: A Case Report and Review of the Literature

The results indicate that targeted therapy with afatinib and osimertinib for EGFR S7688I/V774M and TP53 mutations has better PFS than targeted therapy with furmonertinib and sunvozertinib. Simultaneously, the combination of platinum-based chemotherapy and immunotherapy may be a potential neoadjuvant therapy for NSCLC IVa stage patients.

Authors

Hui Tang (ORCID: https://orcid.org/0000-0002-7274-1487)
Huizhen Peng
Wei Ding (ORCID: https://orcid.org/0000-0002-1421-0661)
Huijuan Zhu (ORCID: https://orcid.org/0000-0002-8045-6539)

Institutions

Zhejiang Chinese Medical University (CN)
First Affiliated Hospital Zhejiang University (CN)
Zhejiang University (CN)

Publication Details

Journal: Case Reports in Oncology
Published: 2025-01-09
DOI: https://doi.org/10.1159/000543453
Citations: 2
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 3.04

Funders

Zhejiang University
Natural Science Foundation of Zhejiang Province

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR Exon 20 S768I Mutant Lung Adenocarcinoma: A Case Report and Review of the Literature

Hui Tang, Huizhen Peng, Wei Ding, Huijuan Zhu

Jan 9, 2025

2 citations

Case Reports in Oncology

Lung Cancer Treatments and Mutations

3.04

article

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR Exon 20 S768I Mutant Lung Adenocarcinoma: A Case Report and Review of the Literature

Hui Tang, Huizhen Peng, Wei Ding, Huijuan Zhu

January 9, 2025article en

2 citations

Abstract

The results indicate that targeted therapy with afatinib and osimertinib for EGFR S7688I/V774M and TP53 mutations has better PFS than targeted therapy with furmonertinib and sunvozertinib. Simultaneously, the combination of platinum-based chemotherapy and immunotherapy may be a potential neoadjuvant therapy for NSCLC IVa stage patients.

Case Reports in OncologyVol. 18(1)

Zhejiang Chinese Medical University (CN), First Affiliated Hospital Zhejiang University (CN), Zhejiang University (CN)

Zhejiang University, Natural Science Foundation of Zhejiang Province

Good health and well-being

Openalex Percentile: Top 12%

Lung Cancer Treatments and Mutations

3.04

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR Exon 20 S768I Mutant Lung Adenocarcinoma: A Case Report and Review of the Literature — Hui Tang, Huizhen Peng, et al. · Case Reports in Oncology (2025) | TGRS Research Map | TGRS